Changes in brain reward systems are thought to contribute significantly to the cognitive and behavioral impairments of schizophrenia, as well as the propensity to develop co-occurring substance abuse disorders. Presently, there are few treatments for persons with a dual diagnosis and little is known about the neural substrates that underlie co-occurring schizophrenia and substance abuse. One goal of the present study was to determine if a change in the concentration of kynurenic acid (KYNA), a tryptophan metabolite that is increased in the brains of people with schizophrenia, affects reward-related behavior. KYNA is an endogenous antagonist of NMDA glutamate receptors and α7 nicotinic acetylcholine receptors, both of which are critically in...
Schizophrenia is a complex disorder with symptoms ranging from hallucinations to poor social functi...
Kynurenic acid is a metabolite of tryptophan and the only known naturally occurring NMethylD-Asparti...
Kynurenic acid is a glutamate receptor antagonist with a preferential action at the glycine/Dserine ...
Changes in brain reward systems are thought to contribute significantly to the cognitive and behavio...
The glia-derived molecule kynurenic acid (KYNA) is an antagonist of a7 nicotinic acetylcholine recep...
Kynurenic acid (KYNA), an end metabolite of the kynurenine pathway along tryptophan degradation, has...
Kynurenic acid (KYNA) is a tryptophan metabolite that is synthesized and released by astrocytes and ...
Rationale: Levels of kynurenic acid (KYNA), an endogenous negative modulator of alpha 7 nicotinic ac...
The tryptophan metabolite kynurenic acid (KYNA) is an endogenous antagonist of the α7 nicotinic acet...
The role of inflammation has become increasingly evident in the pathophysiology of schizophrenia and...
Kynurenic acid, a tryptohan metabolite synthesised in astrocytes, is an endogenous antagonist at gl...
Kynurenic acid (KYNA), an endogenous N-Methyl-D-aspartic acid receptor (NMDAR) antagonist, is elevat...
AbstractKynurenic acid (KYNA), a neuroactive metabolite of tryptophan, is elevated in the brain of p...
Kynurenic acid (KYNA) is an endogenous brain metabolite produced by the kynurenine pathway of trypto...
Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan. Studies have revealed increased bra...
Schizophrenia is a complex disorder with symptoms ranging from hallucinations to poor social functi...
Kynurenic acid is a metabolite of tryptophan and the only known naturally occurring NMethylD-Asparti...
Kynurenic acid is a glutamate receptor antagonist with a preferential action at the glycine/Dserine ...
Changes in brain reward systems are thought to contribute significantly to the cognitive and behavio...
The glia-derived molecule kynurenic acid (KYNA) is an antagonist of a7 nicotinic acetylcholine recep...
Kynurenic acid (KYNA), an end metabolite of the kynurenine pathway along tryptophan degradation, has...
Kynurenic acid (KYNA) is a tryptophan metabolite that is synthesized and released by astrocytes and ...
Rationale: Levels of kynurenic acid (KYNA), an endogenous negative modulator of alpha 7 nicotinic ac...
The tryptophan metabolite kynurenic acid (KYNA) is an endogenous antagonist of the α7 nicotinic acet...
The role of inflammation has become increasingly evident in the pathophysiology of schizophrenia and...
Kynurenic acid, a tryptohan metabolite synthesised in astrocytes, is an endogenous antagonist at gl...
Kynurenic acid (KYNA), an endogenous N-Methyl-D-aspartic acid receptor (NMDAR) antagonist, is elevat...
AbstractKynurenic acid (KYNA), a neuroactive metabolite of tryptophan, is elevated in the brain of p...
Kynurenic acid (KYNA) is an endogenous brain metabolite produced by the kynurenine pathway of trypto...
Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan. Studies have revealed increased bra...
Schizophrenia is a complex disorder with symptoms ranging from hallucinations to poor social functi...
Kynurenic acid is a metabolite of tryptophan and the only known naturally occurring NMethylD-Asparti...
Kynurenic acid is a glutamate receptor antagonist with a preferential action at the glycine/Dserine ...